Drug Trial Radar · NCT04469595
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 31, 2020
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Alimera SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).
Conditions
- Diabetic Macular Edema
Interventions
Iluvien 0.19 MG Drug ImplantDrug
0.19 mg Fluocinolone Acetonide Intravitreal Implant
AfliberceptDrug
2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean total number of supplemental aflibercept injections needed during the studyTime frame: Baseline to 18 months
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site
Phoenix, Arizona
Investigative Site
Tucson, Arizona
Investigative Site
Beverly Hills, California
Investigative Site
Glendale, California
Investigative Site
Laguna Hills, California
Investigative Site
Santa Ana, California
Investigative Site
Colorado Springs, Colorado
Investigative Site
Clearwater, Florida
Investigative Site
Orlando, Florida
Investigative Site
Palm Beach Gardens, Florida
Investigative Site
Tampa, Florida
Investigative Site
Marietta, Georgia
Investigative Site
Sandy Springs, Georgia
Investigative Site
Elmhurst, Illinois
Investigative Site
Lemont, Illinois
Investigative Site
Oak Park, Illinois
Investigative Site
Springfield, Illinois
Investigative Site
Leawood, Kansas
Investigative Site
Shawnee Mission, Kansas
Investigative Site
West Monroe, Louisiana
Investigative Site
Baltimore, Maryland
Investigative Site
Detroit, Michigan
Investigative Site
Grand Blanc, Michigan
Investigative Site
Independence, Missouri
Investigative Site
Bloomfield, New Jersey
Investigative Site
Beachwood, Ohio
Investigative Site
Cincinnati, Ohio
Investigative Site
Cleveland, Ohio
Investigative Site
Youngstown, Ohio
Investigative Site
Tulsa, Oklahoma
Investigative Site
Erie, Pennsylvania
Investigative Site
Columbia, South Carolina
Investigative Site
Dallas, Texas
Investigative Site
Houston, Texas
Investigative Site
McAllen, Texas
Investigative Site
San Antonio, Texas
Investigative Site
San Antonio, Texas
Investigative Site
The Woodlands, Texas
Investigative Site
Roanoke, Virginia
Investigative Site
Warrenton, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.